Sue Washer | Chief Executive Officer |
Mark Shearman | Chief Scientific Officer |
Bill Sullivan | Chief Financial Officer |
Jim Birchenough | Wells Fargo |
Joe Pantginis | H.C. Wainwright |
Matthew Luchini | BMO Capital Markets |
Kristen Kluska | Cantor Fitzgerald |
Zegbeh Jallah | ROTH Capital Partners |
Good morning, and welcome to the AGTC Financial Results Conference call for the Second Quarter of Fiscal Year 2021. Today's call is being recorded.
Before we get started, I would like to remind everyone that during this conference call, AGTC may make forward-looking statements, including statements about the company's financial results, finance, its future business strategies and operations and its product development and regulatory progress, including statements about the projected timing for its planned Vista and SkyLine clinical trials. The timing for reporting data in both of these trials and the potential of its ACHM clinical programs. Actual results could differ materially from those discussed in these forward-looking statements due to a number of important factors.